ObsEva Announces Progress on Restructuring Initiatives : com

$7.6 million annual savings expected via reduction-in-force currently underway$6.2 million savings expected from assignment of legacy linzagolix program...

Related Keywords

Geneva , Genè , Switzerland , Swiss , Yuyuan Bioscience , Shauna Dillon , Katja Buhrer , Brian Ocallaghan , Exchange Commission , Kissei Pharmaceutical Co Ltd , Hangzhou Yuyuan Bioscience Technology Co Ltd , Organon International Gmbh , Swiss Exchange , Nasdaq , Briano Callaghan , Chief Strategy , Nasdaq Stock Market , Nasdaq Listing Rule , Nasdaq Global Select Market , Listing Rule , Nasdaq Global Select , Nasdaq Listing , License Agreement , Sublicense Agreement , Private Securities Litigation Reform Act , Risk Factors , Annual Report , Nasdaq Obsv , Obseva Sa , Obseva ,